NCT02326272View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

PHASE3CompletedINTERVENTIONAL
Enrollment

227

Participants

Timeline

Start Date

December 15, 2014

Primary Completion Date

January 5, 2016

Study Completion Date

September 12, 2018

Conditions
PsoriasisPlaque Psoriasis
Interventions
BIOLOGICAL

Certolizumab Pegol

"* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous use"

OTHER

Placebo

"* Active Substance: Placebo~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous use"

Trial Locations (23)

10025

Ps0002 210, New York

14623

Ps0002 206, Rochester

23294

Ps0002 213, Richmond

28405

Ps0002 209, Wilmington

29650

Ps0002 201, Greer

32174

Ps0002 204, Ormond Beach

44106

Ps0002 205, Cleveland

78213

Ps0002 208, San Antonio

85032

Ps0002 203, Phoenix

90404

Ps0002 212, Santa Monica

93309

Ps0002 214, Bakersfield

97223

Ps0002 200, Portland

03801

Ps0002 207, Portsmouth

08520

Ps0002 202, East Windsor

Unknown

Ps0002 253, Graz

Ps0002 221, Barrie

Ps0002 223, London

Ps0002 222, Peterborough

Ps0002 220, Richmond Hill

Ps0002 224, Waterloo

Ps0002 232, Krakow

Ps0002 231, Wroclaw

Ps0002 230, Kielce

All Listed Sponsors
lead

UCB Biopharma S.P.R.L.

INDUSTRY

NCT02326272 - A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) | Biotech Hunter | Biotech Hunter